ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1486

High Resolution HLA Analysis In Primary and Secondary Sjögren’s Syndrome

Gabriela Hernandez-Molina1, Jose Manuel Rodriguez-Perez2, Nancy Martínez-Rodríguez2, Guadualupe Lima3, Gilberto Vargas-Alarcon4 and Jorge Sanchez-Guerrero5, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubirán, Mexico City, Mexico, 2Department of Molecular Biology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 3Immunology and Rheumatology Department, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubirán, Mexico City, Mexico, 4Molecular Biology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 5UHN Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Sjogren's syndrome and major histocompatibility complex (MHC)

  • Tweet
  • Email
  • Print
Session Information

Title: Sjögren's Syndrome: Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: The Class II HLA-DR and HLA-DQ alleles have been associated with primary Sjögren’s Syndrome (SS) susceptibility. The aim of this study was to explore and compare the distribution of HLA-A, B, DRB1 and DQB1 alleles in patients with primary SS, secondary SS and patients with Connective Tissue Disease (CTD) without (w/o) SS.

Methods: Patients were drawn from a previous study where 50 pSS and 300 CTD patients were randomly selected from our total population of over 5000 patients, and tested for the presence of SS according to the AECG criteria. For the present study we included 28 patients with pSS, 30 patients with sSS and 96 patients with CTD w/o SS with available DNA samples. HLA-A, B, DRB1 and DQB1 were typed by standard PCR-sequencing based typing method.  Serum samples were also examined for anti-Ro/SSA and anti-La/SSB antibodies by ELISA. We used the chi-square analysis or the Fisher’s exact test and the software EPIINFO.

Results: Overall the alleles A*68:01 (a.f. 0.086 vs. a.f 0.02) and DRB1*1406 (a.f. 0.10 vs a.f. 0.008) were associated with SS (OR 4.43 95% C.I. 1.35-14.48, p= 0.007 and OR 14 95% C.I. 1.68-116, p=0.001, respectively). Patients with pSS had a significant higher prevalence of DRB1*1406 than sSS and CTD w/o SS patients (a.f 0.11, a.f 0.09 and a.f 0.008, respectively, OR 16  95% C.I. 1.59-390 p=0.001). Patients with sSS had a higher frequency of the allele A*03:36 when compared with CTD w/o SS patients (a.f. 0.067 vs. a.f 0.005, OR 13.64 95% C.I., 1.40-327, p=0.01). Then we analyzed the patients according to the positivity to anti-Ro/SSA or anti-La/SSB positivity regardless of SS status. Anti-Ro/SSA positive patients had more frequently the allele B*51:01 (a.f. 0.100 vs. a.f. 0.011, OR 10.11 95% C.I. 1-09-245.99, p=0.02) and DRB1*03:01 (a.f. 0.10 vs. a.f 0.027, OR 4.26 95% C.I. 1.01-18.89, p=0.029). The DRB1*03:01 allele was also more prevalent among patients with anti-La/SSB antibodies (a.f. 0.13 vs. a.f. 0.03, OR 4.26 95% C.I.0.93-18.70 p=0.043), as well as the A*01:01 allele (a.f. 0.20 vs. a.f. 0.05, OR 4.75 95% C.I. 1.32-16.92, p=0.003). When we analyzed by generic HLA, we also found an association with DQB1*02 (a.f. 0.23 vs a.f. 0.06, OR 4.16 95% CI 1.32-12.93, p=0.003) and DQB1*04 (a.f. 0.43 vs a.f. 0.07, OR 4.04 95% C.I. 1.63-9.99, p=0.005) and the presence of anti-Ro/SSA antibody.

Conclusion: DRB1*1406 identified patients with both SS varieties whereas B*51:01 and DRB1*03:01 patients with anti-Ro/SSA positivity.


Disclosure:

G. Hernandez-Molina,
None;

J. M. Rodriguez-Perez,
None;

N. Martínez-Rodríguez,
None;

G. Lima,
None;

G. Vargas-Alarcon,
None;

J. Sanchez-Guerrero,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-resolution-hla-analysis-in-primary-and-secondary-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology